Your browser is no longer supported. Please, upgrade your browser.
ANIK Anika Therapeutics, Inc. monthly Stock Chart
Anika Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own0.30% Shs Outstand14.21M Perf Week3.60%
Market Cap548.89M Forward P/E87.93 EPS next Y0.44 Insider Trans-9.82% Shs Float13.99M Perf Month11.19%
Income-4.30M PEG- EPS next Q-0.02 Inst Own98.70% Short Float12.96% Perf Quarter2.19%
Sales127.50M P/S4.31 EPS this Y48.40% Inst Trans-1.92% Short Ratio16.86 Perf Half Y14.08%
Book/sh20.02 P/B1.91 EPS next Y184.30% ROA-1.10% Target Price51.00 Perf Year-33.61%
Cash/sh8.69 P/C4.40 EPS next 5Y10.00% ROE-1.50% 52W Range22.01 - 58.78 Perf YTD-26.23%
Dividend- P/FCF24.84 EPS past 5Y-5.50% ROI8.80% 52W High-34.93% Beta1.06
Dividend %- Quick Ratio4.90 Sales past 5Y1.70% Gross Margin57.60% 52W Low73.78% ATR1.67
Employees154 Current Ratio6.50 Sales Q/Q6.70% Oper. Margin-4.30% RSI (14)57.97 Volatility3.86% 5.04%
OptionableYes Debt/Eq0.09 EPS Q/Q-170.60% Profit Margin-3.40% Rel Volume0.95 Prev Close39.04
ShortableYes LT Debt/Eq0.09 EarningsNov 04 AMC Payout- Avg Volume107.53K Price38.25
Recom2.00 SMA206.43% SMA506.10% SMA2008.95% Volume101,631 Change-2.02%
May-08-20Downgrade Barrington Research Outperform → Mkt Perform
Jan-21-20Upgrade Sidoti Neutral → Buy $61
Jan-10-20Upgrade First Analysis Sec Outperform → Strong Buy $65
Nov-05-19Initiated BWS Financial Sell $29
Sep-24-19Reiterated Barrington Research Outperform $49 → $58
Sep-23-19Downgrade First Analysis Sec Strong Buy → Outperform $54
Jul-25-19Upgrade First Analysis Sec Neutral → Strong Buy $37 → $54
Feb-22-19Downgrade Sidoti Buy → Neutral $56 → $41
Feb-22-19Downgrade First Analysis Sec Outperform → Neutral $41 → $37
Jul-27-18Upgrade Barrington Research Mkt Perform → Outperform $48
Jun-20-18Downgrade First Analysis Sec Overweight → Equal-Weight $45 → $34
Jun-20-18Downgrade Barrington Research Outperform → Mkt Perform
May-04-18Upgrade Barrington Research Mkt Perform → Outperform $39
Feb-23-18Downgrade Barrington Research Outperform → Mkt Perform
Jan-24-18Upgrade First Analysis Sec Equal-Weight → Overweight $45 → $68
Oct-27-17Reiterated Barrington Research Outperform $53 → $57
May-09-16Upgrade Singular Research BUY - Long-Term → Buy $60
Apr-27-16Downgrade Northland Capital Outperform → Market Perform
Feb-26-16Reiterated Barrington Research Outperform $45 → $49
Oct-12-15Initiated Barrington Research Outperform $39
Nov-09-20 08:46AM  
Nov-04-20 09:32PM  
Oct-31-20 08:25AM  
Oct-28-20 12:32PM  
Oct-22-20 04:05PM  
Oct-21-20 04:05PM  
Oct-15-20 12:31PM  
Sep-24-20 11:40AM  
Sep-08-20 04:53PM  
Sep-07-20 11:40AM  
Sep-03-20 02:34PM  
Aug-21-20 11:40AM  
Aug-10-20 07:55AM  
Aug-05-20 04:09PM  
Aug-04-20 11:00AM  
Jul-30-20 07:30PM  
Jul-23-20 12:32PM  
Jul-20-20 07:00AM  
Jul-16-20 04:05PM  
Jul-15-20 12:31PM  
Jun-23-20 11:50AM  
Jun-02-20 04:05PM  
May-12-20 04:05PM  
May-08-20 11:00PM  
May-07-20 04:05PM  
May-01-20 06:34AM  
Apr-28-20 11:40AM  
Apr-27-20 08:30AM  
Apr-23-20 04:05PM  
Apr-08-20 04:05PM  
Apr-02-20 12:45PM  
Mar-26-20 06:12AM  
Mar-11-20 07:51AM  
Mar-04-20 08:30AM  
Feb-27-20 07:52AM  
Feb-21-20 07:46AM  
Feb-20-20 07:15PM  
Feb-13-20 12:31PM  
Feb-12-20 04:05PM  
Feb-06-20 05:14PM  
Feb-04-20 05:38AM  
Feb-03-20 04:30PM  
Jan-29-20 04:30PM  
Jan-24-20 04:05PM  
Jan-13-20 03:00PM  
Jan-08-20 11:47AM  
Jan-06-20 08:30AM  
Dec-30-19 08:22AM  
Dec-24-19 08:57AM  
Dec-20-19 09:28AM  
Dec-19-19 11:35AM  
Dec-17-19 10:25AM  
Dec-16-19 03:44PM  
Dec-13-19 09:25AM  
Dec-12-19 03:19PM  
Dec-11-19 04:11PM  
Dec-10-19 09:26AM  
Dec-09-19 04:31PM  
Dec-06-19 09:26AM  
Dec-05-19 03:53PM  
Dec-04-19 10:25AM  
Dec-03-19 10:45AM  
Dec-02-19 10:22AM  
Nov-28-19 08:10AM  
Nov-27-19 09:00AM  
Nov-25-19 09:18AM  
Nov-22-19 09:45AM  
Nov-21-19 10:24AM  
Nov-20-19 09:50AM  
Nov-19-19 09:40AM  
Anika Therapeutics, Inc., together with its subsidiaries, operates as an integrated joint preservation, restoration, and regenerative solutions company in the United States, Europe, and internationally. The company's lead products include HYALOMATRIX for the treatment of skin wounds, such as pressure ulcers, diabetic foot ulcers, and deep second-degree burns; and MEROGEL, a woven fleece nasal packing. Its joint pain management products comprise MONOVISC, ORTHOVISC, and CINGAL that are used as hyaluronic acid (HA) based viscosupplements to treat osteoarthritis pain in humans; and HYVISC, a HA-based treatment for equine osteoarthritis pain. In addition, the company offers HYALOFAST, a HYAFF-based support for human bone marrow mesenchymal stem cells used for cartilage regeneration and adjunct for microfracture surgery; and Tactoset, a HA-enhanced bone repair therapy to treat insufficiency fractures. Further, it provides ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; joint surface implant and preservation solutions for knee, shoulder, hip, ankle, wrist, and toe to treat upper and lower orthopedic conditions caused by trauma, injury, and arthritic disease; and surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAND RAYMOND JDirectorNov 10Sale36.773,446126,7099,953Nov 12 04:08 PM
Loerop JamesEVP Business DevelopmentJul 09Sale35.151,24443,7271,756Jul 10 04:06 PM
Blanchard Cheryl RPresident, CEO, DirectorApr 26Option Exercise0.004,231011,697Apr 28 06:41 PM
LAND RAYMOND JDirectorFeb 26Sale42.682,700115,23613,399Feb 27 06:54 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.